MedTrace Logo

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

NCT04516447 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2026-04-07

No results posted yet for this study

Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

Conditions

Interventions

DRUG

Azenosertib

Investigational drug

DRUG

Carboplatin

Carboplatin is an approved drug

DRUG

Pegylated liposomal doxorubicin

Pegylated liposomal doxorubicin (PLD) is an approved drug

DRUG

Paclitaxel

Paclitaxel is an approved drug

DRUG

Gemcitabine

Gemcitabine is an approved drug

BIOLOGICAL

Bevacizumab

Bevacizumab is an approved drug

Sponsors & Collaborators

  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bosnia and Herzegovina
  • Bulgaria
  • Georgia
  • Serbia
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516447 on ClinicalTrials.gov